(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo
A phase 2 trial of Avapritinib in systemic mastocytosis, run by Blueprint Medicines Corporation, active and no longer recruiting.
Overview
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis is a phase 2 interventional study registered as NCT03731260 by Blueprint Medicines Corporation, with 251 participants enrolled, started 2019-04-16 and due to reach its primary completion in 2027-06-23. Interventions recorded: Avapritinib, Placebo. Conditions listed: Indolent Systemic Mastocytosis. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TreatmentElenestinib
Shares Systemic mastocytosis, Sanofi.
- Trial(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Shares Systemic mastocytosis, Sanofi.
- CancerGastrointestinal stromal tumour (GIST)
Shares Avapritinib, Systemic mastocytosis, Sanofi.
- TargetKIT
Shares Avapritinib, Systemic mastocytosis.